Riviciclib hydrochloride

Riviciclib hydrochloride

• CAS Number: 920113-03-7
• UNSPSC Description: Riviciclib hydrochloride (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively[1][2]. Riviciclib hydrochloride (P276-00) shows antitumor activity on cisplatin-resistant cells[3].
• Target Antigen: Apoptosis; CDK
• Type: Reference compound
• Related Pathways: Apoptosis;Cell Cycle/DNA Damage
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/Riviciclib_hydrochloride.html
• Solubility: DMSO : 50 mg/mL (ultrasonic)|H2O : 25 mg/mL (ultrasonic)
• Smiles: [H]Cl.O=C1C=C(C2=CC=CC=C2Cl)OC3=C([C@@H]4CCN(C)[C@H]4CO)C(O)=CC(O)=C31
• Molecular Weight: 438.307
• References & Citations: [1]Roskoski R Jr,Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.Pharmacol Res. 2016 May;107:249-275.|[2]Joshi KS, et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. Mol Cancer Ther. 2007 Mar;6(3):918-25.|[3]Joshi KS,et al. P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.Elife. 2020 Dec 7;9:e61405.|Pharmaceuticals. 2024 Apr 29, 17(5), 569.|Int J Mol Sci. 2022 Feb 24;23(5):2493.
• Shipping Conditions: Room Temperature
• Clinical Information: Phase 2